Drugs that contain Acalabrutinib
1. Drug name - CALQUENCE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(4 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
| CN1898240B | ASTRAZENECA | Imidazole And Pyrazine Type Tyrosine Kinase Inhibitor |
Dec, 2014
(7 years ago) | |
| CN1898240A | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Dec, 2014
(7 years ago) | |
| CN103889987A | ASTRAZENECA | As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide |
Jul, 2032
(9 years from now) | |
| CN106243113A | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
| CN103889987B | ASTRAZENECA | Imidazole As Selective Btk Inhibitors And Paradiazine |
Jul, 2032
(9 years from now) | |
| CN106243113B | ASTRAZENECA | As A Selective Btk Inhibitor And Pyrazine |
Jul, 2032
(9 years from now) | |
| CN108349978B | ASTRAZENECA | Solid Forms And Formulations Of (S) -4-(8-Amino - -3-(1 - (But - -2 - Yn-Yl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin-1-Yl) -N-(Pyridine-2-Yl) Benzamide |
Jul, 2036
(13 years from now) | |
| CN108349978A | ASTRAZENECA | (S) -4-(8-Amino - -3-(1 - (But - -2 - Alkyne Acyl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin - -1 - Yl) - N - (Pyridine - -2 - Yl) Benzamide In Solid Form And Preparation |
Jul, 2036
(13 years from now) | |
| IN200601290P4 | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Oct, 2024
(2 years from now) | |
| IN249666B | ASTRAZENECA | Imidazopyrazine Tyrosine Kinase Inhibitors |
Oct, 2024
(2 years from now) | |
| EP1675860B1 | ASTRAZENECA | Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors |
Oct, 2024
(2 years from now) | |
| EP1675860A2 | ASTRAZENECA | Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors |
Oct, 2024
(2 years from now) | |
| EP3689878B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP3689878A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP2734522B1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP2734522A1 | ASTRAZENECA | 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors |
Jul, 2032
(9 years from now) | |
| EP3317281A1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| EP3613745B1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| EP3317281B1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| EP3613745A1 | ASTRAZENECA | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide |
Jul, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(12 years from now) | |
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.